BRPI0515070A2 - sistema de entrega de medicamento auto-emulsificante de butilftalida, sua preparação e método de aplicação - Google Patents

sistema de entrega de medicamento auto-emulsificante de butilftalida, sua preparação e método de aplicação

Info

Publication number
BRPI0515070A2
BRPI0515070A2 BRPI0515070-1A BRPI0515070A BRPI0515070A2 BR PI0515070 A2 BRPI0515070 A2 BR PI0515070A2 BR PI0515070 A BRPI0515070 A BR PI0515070A BR PI0515070 A2 BRPI0515070 A2 BR PI0515070A2
Authority
BR
Brazil
Prior art keywords
delivery system
drug delivery
preparation
self
emulsifying
Prior art date
Application number
BRPI0515070-1A
Other languages
English (en)
Inventor
Zhentao Liu
Liying Yang
Hanyu Yang
Yuqing Gao
Dongmin Shen
Wenmin Guo
Xiaolong Feng
Jia Zheng
Original Assignee
Shijiazhuang Pharma Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharma Group filed Critical Shijiazhuang Pharma Group
Publication of BRPI0515070A2 publication Critical patent/BRPI0515070A2/pt
Publication of BRPI0515070B1 publication Critical patent/BRPI0515070B1/pt
Publication of BRPI0515070B8 publication Critical patent/BRPI0515070B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SISTEMA DE ENTREGA DE MEDICAMENTO AUTO-EMULSIFICANTE DE BUTILFTALIDA, SUA PREPARAçãO E MéTODO DE APLICAçãO. A presente invenção relata um novo sistema de entrega de medicamento, exemplo: sistema de entrega de medicamento auto-emulsificante (SEMAE) de butilftalida, para a preparação deste processo e o sua formulação de uso farmacêutico. O sistema de entrega de medicamento compreende os ingredientes essenciais 1% a 65% de butiíftaíida e 10% a 65% de agente emulsificante, junto com vários excipientes como requerido, dependendo da forma de dosagem desejada. A presente invenção aumenta significantemente a área de contato entre a butilftalida e a membrana mucosa do trato gastro intestinal e portanto melhora a absorção do medicamento.
BRPI0515070A 2004-08-27 2005-08-26 sistema de entrega de medicamentos auto-emulsificante de butilftalida e processo para a preparação do sistema de entrega de medicamentos auto-emulsificante de butilftalida BRPI0515070B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB2004100750682A CN100361656C (zh) 2004-08-27 2004-08-27 丁苯酞自乳化释药体系及其制备方法和应用
CN200410075068.2 2004-08-27
PCT/CN2005/001332 WO2006021160A1 (fr) 2004-08-27 2005-08-26 Système de relargage de médicament auto-émulsifiant à base de butylbenzènephtaléine, méthode de préparation et applications d’un tel système

Publications (3)

Publication Number Publication Date
BRPI0515070A2 true BRPI0515070A2 (pt) 2009-08-04
BRPI0515070B1 BRPI0515070B1 (pt) 2020-09-08
BRPI0515070B8 BRPI0515070B8 (pt) 2021-05-25

Family

ID=35926548

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515070A BRPI0515070B8 (pt) 2004-08-27 2005-08-26 sistema de entrega de medicamentos auto-emulsificante de butilftalida e processo para a preparação do sistema de entrega de medicamentos auto-emulsificante de butilftalida

Country Status (15)

Country Link
US (1) US8728518B2 (pt)
EP (1) EP1787638B1 (pt)
JP (1) JP4653810B2 (pt)
KR (1) KR100887034B1 (pt)
CN (1) CN100361656C (pt)
AT (1) ATE462410T1 (pt)
AU (1) AU2005276811B8 (pt)
BR (1) BRPI0515070B8 (pt)
CA (1) CA2578130C (pt)
DE (1) DE602005020317D1 (pt)
ES (1) ES2341265T4 (pt)
MX (1) MX2007002335A (pt)
NO (1) NO336917B1 (pt)
RU (1) RU2371176C2 (pt)
WO (1) WO2006021160A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100367951C (zh) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
CN101342152B (zh) * 2007-07-10 2010-10-13 石药集团中奇制药技术（石家庄）有限公司 丁苯酞片及其制备方法
CN101579323B (zh) * 2008-05-16 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 丁苯酞缓释片及其制备方法
CN102178643B (zh) * 2011-04-29 2014-05-14 石药集团恩必普药业有限公司 一种丁苯酞或其衍生物的微乳透皮凝胶剂及其制备方法
CN103784424B (zh) * 2012-10-30 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种丁苯酞经皮贴剂及其制备方法
CN109394720A (zh) * 2012-11-21 2019-03-01 石药集团中奇制药技术（石家庄）有限公司 一种3-正丁基苯酞衍生物的组合物及其制备方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
US10799479B2 (en) 2015-04-10 2020-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
CN105796486A (zh) * 2016-03-17 2016-07-27 南京天翔医药科技有限公司 丁苯酞脂肪乳注射剂及其制备工艺
CN107661287B (zh) * 2017-11-28 2021-01-26 遵义医学院 地榆皂苷自乳化药物传递系统的制备
CN110856712B (zh) * 2018-08-06 2021-11-30 刘超 丁苯酞自微乳组合物及其制备方法和用途
CN114073694B (zh) * 2020-08-14 2024-03-12 北京科莱博医药开发有限责任公司 丁苯酞制剂及其制备方法
CN114681389A (zh) * 2020-12-29 2022-07-01 中国科学院上海药物研究所 一种经口腔黏膜递送的丁苯酞组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516477B2 (ja) * 1990-12-17 1996-07-24 花王株式会社 皮膚の血行不良に起因する疾患の治療剤
CN2123000U (zh) 1992-04-24 1992-11-25 李广杰 塑料葡萄灯
DE4313693A1 (de) * 1993-04-27 1994-11-03 Bayer Ag 2-Amino-4-chinolin-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
CN1048158C (zh) * 1993-09-09 2000-01-12 中国医学科学院药物研究所 芹菜甲素在制备预防和治疗哺乳动物或人类脑缺血引起的疾病的药中的应用
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
ATE327735T1 (de) 1998-04-01 2006-06-15 Jagotec Ag Taxan-mikroemulsionen
WO1999056727A2 (en) 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
CN1086942C (zh) * 1998-12-18 2002-07-03 中国医学科学院药物研究所 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs
US6596306B1 (en) 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
SG97918A1 (en) 2000-06-08 2003-08-20 Hovid Sdn Bhd A novel drug delivery system: formulation for fat-soluble drugs
JP2004504342A (ja) * 2000-07-24 2004-02-12 ファルマシア・アンド・アップジョン・カンパニー 極めて水不溶性の脂肪親和性薬剤用の自己乳化性ドラッグデリバリーシステム
CN1166693C (zh) * 2001-06-18 2004-09-15 中奇制药技术（石家庄）有限公司 丁苯酞环糊精或环糊精衍生物包合物及其制备方法和用途
CN1375288A (zh) * 2002-05-13 2002-10-23 周桂荣 一种治疗脑血管疾病的药物组合物
BR0215848A (pt) * 2002-08-21 2005-06-21 Shijiazhuang Pharma Group Complexos de inclusão de butilfitalida com ciclodextrina ou seus derivados, processo para preparação destes e uso dos mesmos
JP4215633B2 (ja) 2002-12-19 2009-01-28 Ｊｆｅケミカル株式会社 複合黒鉛粒子の製造方法
CN1233317C (zh) 2003-07-07 2005-12-28 西安利君制药有限责任公司 水飞蓟素自乳化微乳组合物及其制备工艺

Also Published As

Publication number Publication date
EP1787638B1 (en) 2010-03-31
RU2371176C2 (ru) 2009-10-27
BRPI0515070B8 (pt) 2021-05-25
US8728518B2 (en) 2014-05-20
EP1787638A4 (en) 2008-12-03
NO20071354L (no) 2007-05-29
BRPI0515070B1 (pt) 2020-09-08
CN1726909A (zh) 2006-02-01
AU2005276811B2 (en) 2008-11-13
RU2007111120A (ru) 2008-10-20
AU2005276811B8 (en) 2009-01-22
ES2341265T4 (es) 2011-04-27
WO2006021160A8 (en) 2006-04-13
KR20070046948A (ko) 2007-05-03
ATE462410T1 (de) 2010-04-15
KR100887034B1 (ko) 2009-03-04
AU2005276811A1 (en) 2006-03-02
CA2578130C (en) 2010-08-31
MX2007002335A (es) 2007-10-10
NO336917B1 (no) 2015-11-23
ES2341265T3 (es) 2010-06-17
US20080319056A1 (en) 2008-12-25
DE602005020317D1 (de) 2010-05-12
JP4653810B2 (ja) 2011-03-16
EP1787638A1 (en) 2007-05-23
CN100361656C (zh) 2008-01-16
CA2578130A1 (en) 2006-03-02
JP2008510737A (ja) 2008-04-10
WO2006021160A1 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
BRPI0515070A2 (pt) sistema de entrega de medicamento auto-emulsificante de butilftalida, sua preparação e método de aplicação
Şenel et al. Recent developments in buccal and sublingual delivery systems
CN101325944B (zh) 用于鼻部给药的组合物
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
AR062167A1 (es) Sistema de administracion gastrorretentivo
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
BR0013948A (pt) Prodroga, composição farmacêutica, e, método de tratamento de um paciente mamìfero
BR0211794A (pt) Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
SV1999000152A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
HUP0402154A2 (hu) Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR0208421A (pt) Formulação farmacêutica para administração a um paciente através das mucosas, dose farmacêutica diária, dispersão sólida, uso de pvp em dispersão sólida com 4'-ciano-alfa', alfa', alfa'-trifluoro-3-(4-fluoro fenilsulfonil)-2-hidróxi-2-metilpropiono-m-toluidet o, e, métodos para aumentar a estabilidade em armazenagem, a biodisponibilidade da droga e para reduzir a variação de concentrações de plasma do 4'-ciano-alfa', alfa', alfa',-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2 -metilpropiono-m-toluideto entre pacientes
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
DE602004016403D1 (de) Topische pharmazeutische Zusammensetzungen enthaltend aktive natürliche Bestandteile zur Verhütung und Behandlung von mucosalen Entzündungprozessen
NZ591408A (en) Paracetamol and Calcium carbonate composition
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
EA201170108A1 (ru) Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
BRPI0513186A (pt) composição medicinal para a administração oral
ATE457721T1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
BRPI0510855A (pt) medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis
Perera et al. Thiolated polycarbophil/glutathione: defining its potential as a permeation enhancer for oral drug administration in comparison to sodium caprate
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE O DEPOSITANTE RELATORIO DESCRITIVO, REIVINDICACAO, RESEUMO E DESENHO (SE HOUVER) DE ACORDO COM O ATO NORMATIVO 127 DE 05/03/97.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF